MetaCap

Connect Biopharma (CNTB) vs Dogwood Therapeutics (DWTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Connect Biopharma (CNTB) has outperformed Dogwood Therapeutics (DWTX) over the past year, losing 80.6% versus a loss of 83.7%. Over five years, CNTB leads with a -86.9% price change compared with -99.2% for DWTX. Dogwood Therapeutics is the larger company by market cap ($39.6 million vs $38.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CNTB-80.59%DWTX-83.68%
+27%-31%-89%
Nov 21, 20251 yearNov 20, 2026
CNTB-88.48%DWTX-99.25%
+67%-20%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CNTB versus DWTX key metrics
MetricCNTBDWTX
Share price$0.59$1.04
Market cap$38.05M$39.57M
1-day change-6.08%-2.36%
YTD return-79.08%-75.12%
1-year return-80.59%-83.68%
5-year return-86.89%-99.16%
P/E ratio (TTM)—0.10
EPS (TTM)$-1.14$10.26
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$64.00K—
Revenue growth (YoY)-99.75%—
Net income (latest FY)$-55.48M$-34.26M
Operating margin-90740.63%—
Net margin-86687.50%—
52-week high$3.82$7.04
52-week low$0.55$0.901
Distance from 52-week high-84.55%-85.31%
Analyst consensusstrong_buynone
Avg. price target upside+896.61%+1252.66%
Average volume3.98M89.88K
Shares outstanding64.49M38.23M
Employees648
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Connect Biopharma

CNTB stock →

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).

Health Care · Biotechnology: Pharmaceutical Preparations · 64 employees

About Dogwood Therapeutics

DWTX stock →

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

CNTB vs DWTX FAQ

Which is bigger, Connect Biopharma or Dogwood Therapeutics?

Dogwood Therapeutics (DWTX) is larger, with a market capitalization of $39.57M compared with $38.05M for Connect Biopharma (CNTB).

Which stock has performed better over the past year, CNTB or DWTX?

CNTB returned -80.59% over the past 12 months, compared with -83.68% for DWTX (price return, excluding dividends). Past performance does not predict future results.

Are Connect Biopharma and Dogwood Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons